

# Curtis A Clark

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10415386/publications.pdf>

Version: 2024-02-01

12  
papers

656  
citations

1040056

9  
h-index

1372567

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

1214  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. <i>Cancer Research</i> , 2016, 76, 6964-6974.	0.9	294
2	Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. <i>Blood</i> , 2011, 117, 3199-3208.	1.4	91
3	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, .	17.1	83
4	Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential. <i>Autophagy</i> , 2017, 13, 987-988.	9.1	44
5	Inhibition of Protein Kinase C Attenuates <i>Pseudomonas aeruginosa</i> Elastase-Induced Epithelial Barrier Disruption. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 1263-1271.	2.9	35
6	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. <i>Experimental Gerontology</i> , 2018, 105, 146-154.	2.8	26
7	Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems. <i>Thrombosis and Haemostasis</i> , 2012, 107, 951-961.	3.4	24
8	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020, 80, 5063-5075.	0.9	21
9	Estrogen receptor beta signaling in CD8 <sup>+</sup> T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch. , 2021, 9, e001932.		17
10	Factor X binding to endothelial cell protein C receptor: comparison with factor VIIa and activated protein C. <i>Blood</i> , 2011, 118, 2635-2636.	1.4	10
11	Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 703802.	2.8	10
12	CD122-targeted interleukin-2 and $\pm$ PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. <i>Oncolmmunology</i> , 2021, 10, 2006529.	4.6	1